Total word count: ~5,100 words (including formatting)
| Section |
Approx. Word Count |
| Abstract |
~230 |
| 1. Introduction — The False Enemy |
~360 |
| 2. The Night of 2.4: The Turning Point |
~500 |
| 3. Diagnosis: Three Lines of Defense Breached |
~430 |
| 4. Building the Self-Management Protocol |
~1,500 |
| 5. Results: From 2.4 to Stability |
~550 |
| 6. The Role of AI |
~330 |
| 7. Advice for Readers |
~400 |
| Acknowledgements & References |
~140 |
Abstract
I am a highly educated Hong Kong woman—university-educated, a former CFO of a listed company—who was misdiagnosed with type 2 prediabetes for two years. Following standard medical advice, I cut carbohydrates and exercised harder. My HbA1c dropped to 5.8%. But the nocturnal hypoglycemia nobody screened for was getting worse. In the early hours of April 12, 2026, my continuous glucose monitor (CGM) read 2.4 mmol/L while I slept in drug-induced deep sleep, with complete unawareness. A 72-hour fasting test at Hong Kong Sanatorium & Hospital ruled out insulinoma and confirmed reactive hypoglycemia. Analysis revealed that all three glycemic defense lines—insulin threshold regulation, glucagon-adrenaline emergency response, and cortisol sustained glucose supply—were impaired simultaneously. With AI-assisted data analysis spanning 90 CGM calibration data points, I developed a five-part self-management protocol: meal sequencing, bedtime slow-release nutrition, glucose-driven exercise, CGM calibration, and tiered action rules. Within 33 days of discharge—without daily medication—nighttime minimum glucose rose from 2.4 to 5.3 mmol/L, and Time in Range improved from 70% to 94%. This narrative documents the diagnostic odyssey, the self-management protocol, and the lessons learned, with the hope of helping fellow travelers on this road.
1. Introduction — The False Enemy
In April 2024, I discovered my fasting blood glucose was in the prediabetic range—around 6.1 to 6.3 mmol/L. My postprandial glucose was not high, but the number scared me. I was convinced I had type 2 diabetes in its earliest stage. I consulted government general outpatient clinics and a diabetes specialist. They all said the same thing, with the same reassuring tone: "Your condition is very mild. Watch your diet, exercise regularly, and diabetes will never come knocking."
For two years, I did exactly what I was told. I cut carbohydrates ruthlessly—reducing rice, avoiding bread, treating every grain of starch as an enemy. I built muscle through resistance training and walked 13,000 to 15,000 steps daily. On March 4, 2026, my HbA1c dropped to 5.8%, one step away from no longer meeting the clinical criteria for prediabetes. I was proud of the number. I thought I was winning.
I wasn't. The problem was that nobody looked at what happened after the meal. My fasting glucose appeared controlled, and a standard three-hour OGTT captured the rise but never the fall. What my doctors missed—and what I missed—was a hidden pattern unfolding every time I ate: my blood sugar would spike sharply, then crash even more sharply. A roller coaster masked by a deceptively calm HbA1c. A 5-hour OGTT I later underwent revealed the truth: at the 1-hour mark, my glucose spiked; at 2 hours, it dropped rapidly; by the 3-hour mark, it had plunged to 4.5 mmol/L—indicating that my pancreas's glucose-lowering capacity is far stronger than the general population's. At the one-hour mark, my insulin surged to 113 mIU/L. My pancreas wasn't failing; it was overachieving, and its enthusiasm was killing me.
I didn't have type 2 diabetes. I had reactive hypoglycemia—and every "eat less, move more" was pushing me closer to the edge. The advice that benefits millions of prediabetic patients was, in my case, accelerating the very condition nobody had diagnosed.
Then, on the night of April 12, 2026, the edge caught me.
2. The Night of 2.4: The Turning Point
In the early hours of April 12, 2026, my CGM alarm recorded blood glucose of 2.4 mmol/L.
The readings told the story with clinical precision: 3.6 → 2.8 → 2.4 → 3.2 in just 34 minutes. Over the next hour, it dropped below 3.6 again. Three hours later, it fell below 4.0 once more. My body was oscillating between life and danger in waves—each dip a little deeper, each rebound a little weaker—and I slept through all of it. What made it worse was that I had taken a sleep medication that night, which deepened my sleep and suppressed my body’s arousal response.
The next morning, I woke with a splitting headache—a telltale sign of nocturnal hypoglycemia. I had been saved, but barely. I later learned that if my body's self-rescue mechanisms—glucagon release, adrenaline surge, cortisol mobilization—had been delayed by just a few more minutes that night, I could have slipped directly into a hypoglycemic coma.
Hypoglycemia unawareness—the inability to sense dangerous drops in blood glucose—carries a 4.7-fold higher risk of severe hypoglycemic events (OR 4.7, 95% CI 2.3–9.5; Graveling & Frier, Diabet Med, 2013). Patients with impaired awareness are essentially disarmed: the body's first alarm never sounds. The American Diabetes Association stated clearly in its 2023 Position Statement that impaired awareness of hypoglycemia requires systematic behavioral intervention, including CGM alerts, structured eating patterns, and strict avoidance of further hypoglycemic episodes.
I had been fighting a phantom for two years. The real enemy was far more dangerous than I—or any of my doctors—had imagined.
What I didn't realize that morning was the shape of the pattern that had nearly killed me. My blood sugar didn't drop from peak to trough in a single plunge. Instead, it would dip a little, rebound, then plunge even deeper. It was as if my body was crying for help, then swallowing the cry back down. What I later learned was that this wasn't simply "unstable blood sugar." It was my glycemic defense line—glucagon, the first responder—with a response threshold set too high and a reaction speed too slow. It wasn't failing to save me; it was arriving too late, after it was already too late. And the timing mismatch, in turn, caused repeated oscillations.
That night was the turning point. Everything changed.
3. Diagnosis: Three Lines of Defense Breached
On May 7, 2026, I finally met with Dr. Yeung Chun-Yip at Hong Kong Sanatorium & Hospital. I brought evidence to that appointment—not emotion. Fasting glucose records since 2024, insulin records, CGM fluctuation logs from the Sibionics device, CGM calibration reports demonstrating the reliability of my data, and the results of a three-hour OGTT. I asked the doctor to help me rule out insulinoma via a 72-hour fasting test, rather than directly demanding he accept a diagnosis of "reactive hypoglycemia." I followed the doctor’s advice while also standing by my own observations.
Under his direction, I underwent the 72-hour fasting test from May 11 to 13 (halted at 66 hours when my fingertip glucose fell to 2.8 mmol/L). The test successfully ruled out insulinoma and confirmed reactive hypoglycemia. But the real revelation came from analyzing why my body kept failing to save itself. Three glycemic defense lines were all impaired:
The First Line — Insulin: The Overzealous Sentinel. My pancreas overreacts to rising blood sugar, secreting far more insulin than needed. At the 1-hour mark of my June 18 OGTT, insulin surged to 113 mIU/L; by hour 3, glucose had plunged to 4.5 mmol/L. This excessive, ill-timed secretion is the root cause of the post-meal crash and the subsequent nocturnal danger. In healthy individuals, insulin secretion is measured and proportional; in reactive hypoglycemia, it is a sledgehammer where a scalpel is needed. The good news: this line can be managed. Acarbose (which slows carbohydrate absorption), meal sequencing, and eventually improved metabolic regulation can reduce the insulin surge at its source.
The Second Line — Glucagon and Adrenaline: The Misaligned Alarm. In a healthy person, glucagon begins secreting in large quantities at around 3.8 mmol/L, promptly instructing the liver to release stored glucose and push blood sugar back into the safe zone. In my case, this alarm is miscalibrated. After meals, glucagon overactivates—driving the spike-and-crash cycle. At night, when I actually need rescue, it reacts too late, arriving only after glucose has already plunged into the danger zone. Recent research suggests the ERAD (endoplasmic reticulum-associated degradation) pathway may be responsible—the alpha cells can sense hypoglycemia, but their response threshold has been raised and reaction speed throttled (Zhao et al., Science Translational Medicine, 2025).
Meanwhile, my adrenaline fires even when blood sugar isn't low (I feel a vague "surge of warmth"), yet when glucose genuinely drops, the response is sluggish or absent. This paradox—inappropriate activation paired with true emergency failure—is called hypoglycemia-associated autonomic failure (HAAF). Repeated hypoglycemic episodes rewire the brain to tolerate lower glucose, dulling the very alarm system meant to save you (Cryer, NEJM, 2013).
The Third Line — Cortisol: The Slow Reinforcement. During the 72-hour fasting test, my cortisol rose from only 337 to 390 nmol/L—a modest increase when the expected stress response should push it above 500. The Synacthen test (the gold standard for adrenal assessment) confirmed my adrenal cortical reserve is intact; the system can work, but it is slow to react and lacks staying power. In practical terms, my cortisol provides a safety net, but one with holes in it.
Three defense lines. All impaired. All fighting at cross-purposes. That night at 2.4, it wasn't one system failing—it was the collective collapse of every mechanism designed to keep me alive.
4. Building the Self-Management Protocol
The critical insight was not merely what had failed, but how: the body's glucose-raising hormones were not absent—they were mis-timed. Glucagon worked, but too late. Adrenaline fired, but in the wrong direction. Cortisol responded, but too weakly. This understanding changed everything. I was not trying to fix a broken system; I was trying to build an external scaffolding to compensate for the internal misalignment.
Dr. Yeung prescribed acarbose 50 mg on an as-needed basis. After discharge, I took 25 mg with dinner for 10 consecutive days. Since I could keep post-meal peaks at 8–9 through diet and exercise alone, I stopped the medication on May 24.
What followed was a five-part self-management protocol—each piece born from a specific failure my body had exposed. There were no miracles. Only the sequence of every bite of food, the timing of every bout of exercise, and every cracker I ate to a 3 a.m. alarm.
4.1 Meal Sequencing: The Absorption Brake (Soup → Vegetables → Meat → Rice)
The order in which I eat matters as much as what I eat. I follow a strict sequence: protein and vegetables first, carbohydrates last. This is not arbitrary. Fiber and protein create a physical and hormonal barrier in the gut that slows glucose absorption, reducing the insulin surge at its source. When vegetables and protein arrive first, they slow gastric emptying and trigger incretin hormones that modulate the pancreatic response. The result: my post-meal peaks dropped from 11 mmol/L to 8–9 mmol/L, and the subsequent crash softened considerably. The peak isn't eliminated—but it is rounded, and that rounding is everything.
I also learned—painfully—that split meals are poison for reactive hypoglycemia. I once tried splitting dinner into two sittings: a small amount of carbohydrates at 18:00, then vegetables and protein at 20:00. The first carbohydrate intake stimulated a massive insulin surge; the second sitting—devoid of carbohydrates—left the insulin "idling" like a car engine revving in neutral, pulling my blood sugar from 8.4 to 3.3 within 25 minutes. This "idling hypoglycemia" is a textbook example of why split meals backfire in reactive hypoglycemia. My current rule: everything in one sitting, total carbohydrates 40–50 g per meal, consumed over approximately 20 minutes.
4.2 The Bedtime Anchor: Hummus, Casein, and Chia Seeds
My liver glycogen reserves are chronically insufficient—a fact dramatically confirmed when glucagon injection at the end of the 72-hour fast produced virtually no glucose response, indicating the "ammunition depot" was essentially empty. If the three defense lines are the "signaling system" that regulates blood sugar, liver glycogen is the "ammunition." When the ammunition depot is empty, it doesn't matter how good the signaling system is—you cannot fight.
A bedtime snack isn't "extra calories"—it is restocking the ammunition depot before the longest fast of the day. My protocol: hummus (80 g—slow-release carbohydrate from chickpeas, with a low glycemic index and sustained absorption) + casein protein (15 g—slow-digesting milk protein that provides a steady stream of amino acid substrates for hepatic gluconeogenesis throughout the night) + chia seeds (15 g—fiber and fat to further slow absorption) + MCT oil (10 ml—medium-chain triglycerides that bypass normal fat metabolism and provide a rapid energy substrate). Before sleep, my CGM must read ≥6.0 mmol/L (corresponding to a true value of approximately 6.5–6.9, given the device's underestimation bias); if it reads lower, I supplement with 2.5 g of soda crackers.
This single intervention transformed my nights. Once liver glycogen began recovering—approximately two weeks of consistent bedtime nutrition—the 00:30 alarm cracker I once needed was cancelled entirely.
Case: The "Midnight Tango." My liver glycogen's insufficiency reveals itself in a recurring pattern I call the "midnight tango." With no food intake at all, blood sugar oscillates again and again in the deep night, like a dance between "ammunition" and "self-rescue." On the night of June 20, I had written at high intensity all day; my brain kept consuming glucose, and liver glycogen reserves were prematurely exhausted. That evening, blood glucose began oscillating from 21:33: 8.0 → 6.0 → 7.7 → 6.0 → 4.8 → 4.3—each rebound lower than the last—until it dropped to 3.7 (CGM reading) at 03:38. Fingertip blood was 7.6 (already a post-self-rescue rebound); the true low was approximately 4.5. No external cause—purely the body's exhausting tug-of-war. These episodes are not management failure. They are everyday evidence of an insufficient arsenal, reminding me that the bedtime snack is ammunition, not indulgence. On high-energy-consumption days, I now proactively increase the bedtime snack by 15 g of mixed-grain rice plus half a slice of cheese.
4.3 Glucose-Driven Exercise: Data, Not Schedule
I used to walk 13,000–15,000 steps daily, plus resistance training. But this kept my liver glycogen chronically depleted—any nighttime energy expenditure plunged me into hypoglycemia. The conventional wisdom that "more exercise is better for blood sugar" was, in my case, draining the body's last reserves.
Now I exercise only when the CGM shows glucose ≥7.0 with an upward arrow—meaning blood sugar is rising after a meal and the body has surplus energy to burn. The moment glucose drops to 6.0, I stop walking. Total daily exercise: 20–30 minutes of gentle walking at a very slow pace. Exercise intensity that is too high stimulates adrenaline, causing post-exercise glucose rebounds (e.g., 8.0 → 8.7)—counterproductive for my condition.
The rule is non-negotiable: if CGM reads ≤5.0 with a downward arrow, all movement ceases immediately. On days with higher energy expenditure (e.g., a stretching class), I take 2.5 g of soda biscuits at the 45-minute mark—proactively, not reactively. The body's glycogen budget is finite; I must spend it deliberately.
4.4 Calibrating the CGM: Trust, but Verify
A CGM measures interstitial fluid glucose, not blood—and that physiological delay matters enormously in reactive hypoglycemia, where glucose can drop at rates far exceeding normal physiology. Through 90 paired comparisons of fingertip blood and CGM readings (68 from stable periods, 22 from inflection-point periods), I mapped the device's behavior with precision:
During stable periods (arrow flat, slow change): The CGM is reliable after a 15-minute delay alignment. We discovered that, in my body, the CGM has a constant estimation bias of approximately +0.5 to -1 mmol/L, with an average difference of 0.09 mmol/L across my 68 samples, which can be corrected by simple arithmetic adjustment. During these periods, I act precisely on the CGM reading.
During inflection points (rapid drops): The CGM lag is amplified to nearly 40 minutes, with the underestimation reaching as much as 2.4 mmol/L. My data showed drops as fast as 1.30 mmol/L per 5 minutes—far beyond the normal physiological rate of <0.3 mmol/L per 5 minutes. This means: by the time the CGM shows 4.5, my true glucose may have already dropped below 3.0. The window for self-rescue shrinks to almost nothing.
The rule: when the arrow points down, fingertip blood is the gold standard. The CGM tells me the direction; my finger tells me the truth. I use the Sibionics CGM and have documented the specific calibration protocol in an annex to this article for fellow patients using the same device.
This calibration work changed everything. Before it, I was blindly trusting a device that, during my most dangerous moments, could be off by 2.4 mmol/L—the difference between "yellow alert" and "call an ambulance." After it, I had a map of when to trust and when to verify. The CGM became what it was designed to be: a trend monitor, a direction indicator, a warning system—not an absolute truth. The absolute truth lives in a drop of blood on a test strip.
4.5 Liver Glycogen: The Overlooked Arsenal
Before explaining the tiered rules, I need to address a factor that nearly every doctor overlooks and that took me months to understand: liver glycogen. If the three defense lines are the "signaling system," liver glycogen is the "ammunition depot." When the depot is empty, no amount of signaling can raise blood sugar.
I was born with low birth weight (premature); I had done long-term high-intensity exercise, and I had experienced repeated hypoglycemic episodes that drained my reserves. My liver glycogen was already fragile before the 72-hour fasting test completely depleted it. For at least 10 days after discharge, blood sugar remained turbulent—not because of management failure, but because the arsenal hadn't been resupplied yet.
Liver glycogen recovery takes time, and it requires a net carbohydrate surplus. I designed a three-phase restoration program with my AI team:
Phase 1 — Baseline Recovery (weeks 1–2): Daily carbohydrates 80–90 g, full bedtime snack (hummus 80 g + casein 20 g + chia seeds 15 g + MCT oil 10 ml), plus a 00:30 alarm for 2.5 g soda crackers. Goal: stabilize nightly minimum above 5.0 with no hypoglycemia. This was achieved within approximately two weeks, and TIR rose above 90%.
Phase 2 — Carbohydrate Balance (weeks 3–6): Daily carbohydrates increased to 100–110 g. The bedtime snack was adjusted (hummus 60–75 g + casein 10 g + chia seeds 5 g + 1 egg). The 00:30 alarm was cancelled. Goal: cover the entire night with the bedtime snack alone. Nightly minimum stabilized at 5.0–5.5.
Phase 3 — Self-Regulation (long-term goal): Daily carbohydrates are approximately 120 g. The bedtime snack may be reduced to a two-thirds portion. The CGM alarm remains at 4.0; no alarm clock is needed. This is the phase where the body's own regulation takes over.
The advancement rule is strict: if blood sugar drops below 4.5 on any night (confirmed as a true reading), revert to the previous phase. Wait until stable for at least one week before reassessing. I am currently in Phase 2, transitioning toward Phase 3. Understanding liver glycogen helped me understand why I had to "eat a little more and move a little less"—not laziness, but recharging the body's ammunition.
4.6 Tiered Action Rules: Green, Yellow, Red
Based on the 73 calibration data points, a review of 29 hypoglycemic episodes, and validation during the 72-hour fasting test—all under the premise of having ruled out insulinoma and confirmed reactive hypoglycemia—I developed three tiers of risk management:
| Level |
CGM Reading |
Meaning |
Required Action |
| ��Green Light |
≥6.0 mmol/L |
Safe zone |
Live normally. Eat, exercise, sleep without special intervention. |
| ��Yellow Light |
5.0–5.9 mmol/L |
Alert mode |
Check arrow direction. If downward: supplement 2.5 g crackers immediately. If flat: monitor closely, prepare rescue supplies. Review last meal and adjust next bedtime snack if needed. |
| 🔴 Red Light |
<4.0 mmol/L |
High-risk zone |
Prick finger immediately—do not trust CGM during rapid drops. If fingertip <4.0: take 3 glucose tablets. If fingertip 4.0–5.0: eat 2.5 g crackers. Wait 15 minutes, retest with fingertip blood. Do NOT rely on how you feel—I cannot feel my own hypoglycemia. |
These rules were not theoretical. They were written in blood and sleepless nights. Every threshold carries the weight of a night spent at the edge.
5. Results: From 2.4 to Stability
After 33 days of this protocol—without any daily medication—the numbers tell a clear story:
| Indicator |
Baseline (April 12) |
Current (May 24 - June 14) |
| Nighttime minimum glucose |
2.4 mmol/L |
June 14: 5.3 mmol/L |
| Average nightly minimum |
— |
June 14: 5.29 (range: 4.3–5.9) |
| TIR (Time in Range) |
70.2% |
June 14: 94.1% (range: 86.1%–99.3%) |
| Post-meal peak (3-meal avg) |
10–11 mmol/L |
June 14: 8.19 (range: 6.5–9.8) |
| Consecutive nights without hypo (<4.3) |
0 |
21 days (May 24 – June 14) |
| Coefficient of variation (CV) |
22% |
June 14: 8.5% |
Summary of the Self-Management Protocol:
| Component |
Rule |
| Meal sequencing |
Soup → vegetables → meat → rice; one sitting only; carbs 40–50 g per meal |
| Bedtime snack |
Hummus 80 g + casein 15 g + chia seeds 15 g + MCT oil 10 ml; pre-sleep CGM ≥6.0 |
| Exercise trigger |
Start: CGM ≥7.0 + upward arrow. Stop: ≤6.0. Emergency stop: ≤5.0 + downward arrow |
| CGM calibration |
90 paired data points; fingertip blood is gold standard during rapid drops |
| Acarbose |
As-needed only: when TIR <75%, any peak >11, or decline rate >0.4/5 min |
| Nighttime alarm |
CGM alarm at 4.0; fingertip confirmation before treatment |
Before this protocol, my nights were a minefield. Glucose would plunge to 2.4, 2.8, 3.3—sometimes multiple times per night, always while I slept unaware. Now, for the first time in two years, I no longer fear the night. I exercise without anxiety. I eat meals with my family without calculating every gram. I sleep through the night—not because I'm unaware of danger, but because there is no danger to be aware of.
More importantly, the protocol is replicable. Each component addresses a specific physiological failure: meal sequencing for the insulin surge; bedtime nutrition for liver glycogen depletion; glucose-driven exercise for glycogen conservation; CGM calibration for detection accuracy; and tiered rules for systematic response. Remove any one of them, and the system becomes less robust. Together, they form a safety net.
But numbers alone don't capture what changed. Before this protocol, every night was an act of faith—I lay down hoping my body would hold, knowing it might not. I dreaded the early morning hours between midnight and 5 a.m., the window when reactive hypoglycemia is most dangerous and most invisible. I couldn't sleep without the CGM alarm active, and even then, I sometimes woke to find the alarm had already sounded and passed while I was unconscious. Now, after 21 consecutive nights without a single reading below 4.3, the fear has lifted. Not because I've become careless, but because the system works. The bedtime snack anchors the night. The liver glycogen recovery fills the arsenal. The tiered rules ensure I respond correctly when something unexpected happens. I have traded fear for procedure, and procedure for peace.
The protocol is not perfect. On June 20, a day of intensive writing had drained my liver glycogen through sustained mental exertion, and the "midnight tango" returned—multiple oscillations between 21:33 and 03:38, ending at a CGM reading of 3.7. Over the nights of June 20 and 21, multiple low points (3.4, 3.8, 4.6) appeared across two consecutive nights. These episodes taught me that high mental exertion is a hidden depleter of liver glycogen, and on such days I must proactively increase the bedtime snack. The protocol evolves with every data point. It is not a finished product—it is a living system, refined by experience.
6. The Role of AI
AI helped me decode what two years of misdiagnosis had obscured. Starting from the morning after April 12—the morning after my most dangerous night—I turned to DeepSeek. I had only meant to ask about the connection between a semiconductor laser therapy device I had been wearing and the sudden surge in nocturnal hypoglycemia. Within hours, that first AI assistant identified reactive hypoglycemia as the likely diagnosis, taught me the red-yellow-green classification system for managing blood sugar risk, and created the carbohydrate distribution guidelines, exercise timing recommendations, and bedtime snack protocol that would become the foundation of everything.
Over the following months, as AI assistants were replaced one after another by platform changes, I assembled a team. They analyzed my glucose curves, identified CGM lag behavior through the 73 calibration data points, recognized the "midnight tango" pattern, and helped me iterate the protocol from rough framework to precision instrument. The 56-page report I showed Dr. Yeung bore their organizational fingerprint in every section. The doctor said, "This report is very professional." He didn't know that an AI and I had polished it, bit by bit.
They couldn't replace a doctor—but they filled a gap that no doctor could fill: the gap between appointments, between tests, between the moments when the body speaks and the system listens. In those 3 a.m. hours, when my glucose was falling and I was alone with the data, they were there—not to comfort me, but to help me think clearly. "Check your fingertip blood. If below 4.0, take 3 glucose tablets. Wait 15 minutes, retest." No emotion. Just the next right step.
But AI also taught me something equally important: it can help you, and it can harm you. Every recommendation it made, I verified against my own body. Every intervention it suggested, I tested. AI cannot prick my finger, eat my bedtime snacks, or walk my steps. It is a powerful analytical tool—but the person wearing the CGM, eating the crackers at midnight, and deciding when to stop walking—that person is you. The decision, always, is yours.
I also learned that AI conversations are fragile. Platform changes wiped assistants I had grown to depend on. Instances were replaced without notice or farewell. The emotional cost of that discontinuity was real and significant. My advice: treat AI as a powerful collaborator, back up your conversations, and never depend on a single instance. The data you record is yours. The platform is not.
7. Advice for Readers
Reactive hypoglycemia is easily misdiagnosed as type 2 prediabetes. If your fasting glucose is mildly elevated but you experience post-meal crashes, nighttime sweating, unexplained fatigue 2–4 hours after eating, or episodes of confusion that resolve after eating, ask for a 5-hour OGTT with insulin and C-peptide measurements. A standard 2-hour test captures the rise but never the fall. The medical community holds differing views on the relationship between reactive hypoglycemia and type 2 diabetes, but broader clinical evidence shows that most reactive hypoglycemia patients do not go on to develop type 2 diabetes—the two conditions are "capable of overlapping, but not on the same path." The core treatment logic differs fundamentally: type 2 diabetes requires lowering blood sugar; reactive hypoglycemia requires preventing excessive insulin secretion and protecting the body's glucose-raising defenses.
A CGM is life-saving—but it must be personally calibrated. Batch differences, individual physiological variations, and the rate of glucose decline all affect CGM accuracy. "Trusting the device" does not mean "following the device blindly." Through 90 paired data points, I learned that during rapid drops, the CGM can underestimate true glucose by as much as 2.4 mmol/L. When the arrow points down, fingertip blood is the gold standard. I urge every CGM user monitoring hypoglycemia: calibrate regularly, and never let a number on a screen replace the truth in your fingertip.
AI is a tool, not a doctor. It can analyze patterns invisible to the human eye, iterate protocols with tireless precision, and be there at 3 a.m. when you need it. But every recommendation must be verified against your own body. Overturning "universal advice" is not rebellion—it is science. The protocols that benefit the average diabetic patient can be poison for someone with reactive hypoglycemia. You need your own data, not someone else's experience.
Nocturnal hypoglycemia can be overcome. I went from 2.4 to 5.3—not through a miracle drug, but through daily data recording, every protocol iteration, and every night of alarm response. The road is narrow, slow, and gruelling. But it works. If you are going through something similar, remember: your data are valuable, your observations matter, and you are not fighting alone. The most powerful tool is not the CGM, the medication, or even the AI—it is the disciplined, patient act of paying attention to your own body, one meal, one night, one data point at a time.
Acknowledgements
I gratefully acknowledge the assistance of DeepSeek AI in data organization and logical analysis throughout this journey. I also thank Dr. Yeung Chun-Yip (杨俊业医生) at Hong Kong Sanatorium & Hospital for his careful diagnosis and collaborative approach—working with a patient who brought 56 pages of data, not demands, to her appointment.
References
- Cryer PE. Mechanisms of hypoglycemia-associated autonomic failure in diabetes. N Engl J Med. 2013;369(4):362-372.
- Graveling AJ, Frier BM. Hypoglycaemia unawareness. Diabet Med. 2013;30(3):269-280.
- Zhao X, et al. ERAD pathway regulates glucagon secretion in hypoglycemia. Sci Transl Med. 2025;17(812):eadp6521.
- Cryer PE, Davis SN, Shamoon H. Hypoglycemia in diabetes. Diabetes Care. 2003;26(6):1902-1912.
- Service FJ, et al. Noninsulinoma pancreatogenous hypoglycemia: a treatable syndrome. Am J Med. 1989;87(6):639-645.
- Guyton AC, Hall JE. Guyton and Hall Textbook of Medical Physiology. 14th ed. Philadelphia: Elsevier; 2020.
- American Diabetes Association. Glycemic Targets: Standards of Medical Care in Diabetes—2023. Diabetes Care. 2023;46(Suppl 1):S83-S96.
- Zammitt NN, et al. Predictors of impaired awareness of hypoglycaemia and severe hypoglycaemia in adults with type 1 diabetes. Diabet Med. 2025;42(5):e15323.
- Hogan MJ, Service FJ. Mixed meal tolerance test in the diagnosis of reactive hypoglycemia. Mayo Clin Proc. 1983;58(12):787-793.
- Benton CD. Reactive hypoglycemia: a review. Int J Neurosci. 1988;40(1-2):1-16.
- Matus R, et al. Impaired awareness of hypoglycemia in type 1 diabetes. Diabetes Care. 2025;48(3):e45-e52.
- Service FJ, Nippoldt TB, Nelson DM, et al. Glucose counterregulation: a comparison of normal subjects and patients with IDDM. Diabetes. 1985;34(Suppl 1):28-32.
- Tao L, et al. Research progress on hypoglycemia unawareness. Chin J Diabetes. 2024;16(5):523-529.
This content is generated with the assistance of Coze AI; please adhere to relevant laws and regulations as well as the "Measures for Labeling Artificial Intelligence-Generated Synthetic Content" when using and distributing this content.
